Cellecta Announces Upcoming Presentations at AACR 2018

Cellecta, Inc. announced that it will deliver three scientific presentations at the upcoming American Association for Cancer Research (AACR) 2018 Annual Meeting, which will take place April 14-18, 2017 at the McCormick Place Convention Center in Chicago, Illinois. Cellecta researchers and an academic collaborator will present unpublished data on technology developments for genetic screens in human cancer cell lines using CRISPR-knockout, CRISPRi-repression, and CRISPRa-activation; as well as new data on application of the DriverMap targeted RNA expression profiling for drug screening and biomarker discovery.

Details of the presentations are as follows:

Spotlight Theatre Presentation: Genetic Profiling and Functional Screening for Drug Target and Biomarker Discovery

• Date and Time: Monday, April 16, 2017, 10:00 – 11:00 a.m. Central Time
• Location: McCormick Place Convention Center, Spotlight Theatre C – Exhibit Hall

The Spotlight Theatre will include the following presentations:

Efficient Tools to Enable Drug Target and Biomarker Discovery: A Brief Introduction to Cellecta Technologies – Paul Diehl, Ph.D., Chief Operating Officer, Cellecta

Optimization of CRISPR Technology for Large-Scale Genetic Screens – Sylvain Baron, Ph.D., Research Scientist, Cellecta

DriverMap™ Transcriptome Profiling: Applications in Drug Screens and Biomarker Discovery – Lester Kobzik, M.D., Professor of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Harvard School of Public Health

Poster Abstract LB-379/ Poster 7: Targeted single-cell RNA expression profiling for cellular characterization of the tumor microenvironment

• Session: Late-Breaking Research: Molecular and Cell Biology
• Date and Time: Wednesday, April 18, 2018, 8:00 a.m. - 12:00 p.m. Central Time
• Location: McCormick Place Convention Center Exhibit Hall, Poster Section 45

Cellecta, a provider of genomic products and services, is an industry leader in RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets, and genetic profiling for biomarker discovery. Cellecta’s functional genomics portfolio offers gene knockout and knockdown screens, custom and genome-wide RNAi and CRISPR libraries, cell engineering, RNAi and CRISPR construct services, targeted expression profiling, and biomarker discovery of disease samples. The DriverMap™ Human Genome-Wide Targeted Expression Profiling Assay enables researchers to simultaneously measure the expression level of almost 19,000 human protein-coding genes in a single assay.

Download Cellecta's Driver-Map^TM expression profiling solutions brochure here